Novartis | NOVN - Operating Expenses

Stock Price
126.46
Daily Change
-0.02 -0.02%
Monthly
10.60%
Yearly
28.84%
Q1 Forecast
123.39

Novartis reported $9.86B in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Alcon AG USD 2.28B 67M Sep/2025
Almirall EUR 517.43M 43.18M Jun/2025
Amgen USD 5.9B 773M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Autolus Therapeutics Ltd USD 82.61M 8.39M Jun/2025
Bayer EUR 10.2B 523M Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Fresenius EUR 4.91B 110M Sep/2025
Fresenius Medical Care EUR 4.43B 73.91M Sep/2025
Galapagos EUR 112.83M 9.48M Sep/2025
Genmab DKK 565M 38M Jun/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
GRIFOLS EUR 1.51B 28.3M Sep/2025
Hikma Pharmaceutical USD 642M 663M Jun/2025
J&J USD 18.97B 2.38B Dec/2025
Lonza CHF 3.09B 564M Dec/2024
Merck EUR 4.11B 117M Sep/2025
Merck USD 10.16B 558M Dec/2025
Novartis USD 9.86B 115M Sep/2025
Novartis USD 9.77B 401M Sep/2025
Novo Nordisk DKK 46.76B 3.99B Dec/2025
Orion EUR 367.1M 64.9M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Philips EUR 4.38B 405M Dec/2025
Recordati EUR 466.68M 27.25M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
UCB EUR 2.36B 108M Dec/2024